Camizestrant Approval: First ctDNA-Guided Cancer Care

The camizestrant U.S. FDA approval on 4 September 2026 is the first cancer approval guided by circulating tumour DNA (ctDNA) before imaging shows progression.

The FDA backed a monitor-and-switch strategy, not just a molecule, after its own advisers voted against it. What changed and what sponsors should do next?

Image

The First ctDNA-Guided Cancer Approval Explained

On 4 September 2026, the Food and Drug Administration (FDA) granted AstraZeneca accelerated approval for Etcamah (camizestrant), an oral selective oestrogen receptor degrader.

Doctors prescribe Etcamah with a CDK4/6 inhibitor: Abemaciclib, palbociclib, or ribociclib. The FDA announcement covers adults with HR-positive, HER2-negative, locally advanced or metastatic breast cancer. Treatment starts only when an ESR1 mutation appears during aromatase inhibitor and CDK4/6 inhibitor therapy.

The FDA also authorised the Guardant360 CDx blood test to find eligible patients. This makes it the first ctDNA-guided cancer approval that acts before imaging shows progression.

This is a real milestone.

The FDA did not only approve a drug but also accepted a monitoring-and-switch strategy, in which a blood test triggers a therapy change before scans show worsening disease.

That makes the diagnostic, the testing schedule, and the clinical pathway all part of the one regulatory package.

ESR1 mutations in breast cancer patients

ESR1 mutations are acquired resistance mutations. The FDA reports that fewer than 5 per cent of patients carry one at diagnosis, yet nearly 40 per cent do after progression on an aromatase inhibitor.

AstraZeneca estimates that about 30% of patients with endocrine-sensitive disease develop one during first-line treatment, before progression.

In theory, earlier detection lets doctors switch therapy while tumour burden is lower and patients may still be healthier. The FDA has not yet confirmed that this timing translates into clinical benefit.

What did the FDA approval require?

• Trigger: An ESR1 mutation found in blood during first-line therapy, before imaging shows progression.
• Regimen: Camizestrant replaces the aromatase inhibitor, and the same CDK4/6 inhibitor continues.
• Status: Accelerated approval, so confirmatory studies must verify clinical benefit.
• Safety: A boxed warning covers irregular heart rhythm when certain concomittant medicines.

However, Angelo de Claro, director of the FDA’s Oncology Center of Excellence, said more evidence is needed to confirm clinical benefit. 

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

Why Did the FDA Overrule Its Own Advisory Panel?

The FDA does not have to follow its advisory committees, and here it chose not to.

The agency used the accelerated approval pathway to act on a strong early signal while it waits for firmer proof. 

The committee voted no

On 30 April 2026, the Oncologic Drugs Advisory Committee voted six to three that SERENA-6 did not show clinically meaningful benefit.

Members questioned whether the trial proved that early switching beats waiting for imaging progression. Several also wanted overall survival (OS) data first.

The FDA approved the drug about four months later, with confirmatory conditions attached.

That split shows a live debate. A strong progression-free survival gain won the trial a regulatory path, yet a majority still wanted proof that timing, not just the new drug, drives the benefit.

Image

What does SERENA-6 evidence show?

SERENA-6 enrolled 315 adults on first-line aromatase inhibitor and CDK4/6 inhibitor therapy.

Investigators tested blood for ESR1 mutations at routine scan visits every two to three months. Patients with a new mutation and no progression either switched to camizestrant or stayed on their aromatase inhibitor, with the same CDK4/6 inhibitor in both arms.

This double-blind design was implemented to specifically strengthen confidence in the progression-free survival outcomes.

• Median progression-free survival (PFS) reached 16.0 months versus 9.2 months, with a hazard ratio of 0.44 at interim analysis.
• Updates at ASCO 2026 showed time to second progression of 25.7 months versus 19.1 months.
• ctDNA clearance reached 51.0% with camizestrant, against 1.9 per cent with continued aromatase inhibitor therapy.
• OS data remain immature, with a hazard ratio of 0.87 and a wide confidence interval.

Safety matched the known profile of each CDK4/6 inhibitor, and AstraZeneca reports no new safety concerns.

What the data cannot prove — yet

The central gap is trial design.

SERENA-6 compared early switching with staying on the aromatase inhibitor. It did not compare early switching with switching at imaging progression.

The FDA notes that this question remains unconfirmed, which is why it required confirmatory studies.

A convincing confirmatory study would likely test timing directly, or follow patients long enough to show a durable survival gain. Either route takes years, so the label will carry uncertainty for some time.

Some experts argue OS is confounded by uneven global drug access and was never the primary question.

Both views carry weight. For decision-makers, the real issue is what evidence bar an early-switch design must clear when survival data are immature.

Camizestrant FDA Approval Raises Diagnostic and Payer Questions

The camizestrant FDA approval raises two practical questions for decision-makers: Who runs the test, and who pays for it?

The treatment switch depends on a blood test, so the diagnostic and the drug now share one regulatory and commercial path.

There are certain important factors to consider across regions for what repeat testing costs, and what safety monitoring requires.

Drug and diagnostic approval in one regulatory pathway

The FDA authorised Guardant360 CDx as the companion diagnostic at the same time as the approval for camizestrant.

On 9 October 2026, the test also received CE marking under the EU In Vitro Diagnostic Medical Devices Regulation (IVDR) for camizestrant. That followed approvals in the U.S. and Japan, and it was the third companion diagnostic approval for the drug.

For sponsors, three regulatory lanes now exist. The FDA authorised the test alongside the drug, Japan approved a matching diagnostic, and the EU certified it through the IVDR.

However, each system uses its own documentation, so a single evidence package rarely travels unchanged.

The indication depends on an FDA-authorised test, so assay performance now underpins prescribing decisions.

AstraZeneca says the drug itself is approved in more than 30 countries, including the EU. Sponsors must therefore co-develop, validate, and file the test alongside the molecule across several regulatory systems. A delay in one lane can slow the whole launch.

EU rules on diagnostics and software sit at the centre of Pharmatica Insights into the Biotech Act and AI Act. The same logic applies here. The FDA’s device centre is also reshaping its approach to rare disease, which we cover in our CDRH rare disease initiative Insights.

The cost of repeat testing

SERENA-6 did ctDNA testing every two to three months.

Importantly, this schedule demands technical and financial resources beyond many public systems and private insurers.

AstraZeneca counts about 37,000 U.S. patients treated in the first-line setting for HR-positive metastatic disease. Finding the roughly 30% who develop a mutation means testing that whole population repeatedly.

Payers will ask a fair question. Does earlier switching improve outcomes enough to justify the testing bill?

The answer depends on confirmatory data, so reimbursement may stay uneven for now.

Laboratories also need turnaround times that fit clinic visit schedules.

Safety adds monitoring work

The boxed warning links the drug to QTc interval prolongation, especially alongside ribociclib. Prescribers must run an ECG before treatment and weekly during the first two weeks.

Oncology teams will therefore juggle ctDNA schedules, imaging, and cardiac checks. Clinics that already struggle with capacity will feel that workload first.

Read The Looming Threat of Geopolitical Risk in Clinical Supply Chains

The Looming Threat of Geopolitical Risk in Clinical Supply Chains

Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.

Image

Strategy Approvals Set a New Bar for Sponsors

This camizestrant FDA approval demonstrates that regulators will weigh strategies, not only single drugs or therapuetic regimens.

Sponsors seeking a ctDNA-triggered label should plan four things early:

• Randomise the strategy. Compare early switching with switching at imaging progression, not only with continued therapy.
• Lock the biomarker pathway. Fix assay performance, test timing, and mutation thresholds before enrolment.
• Plan the survival story. Pre-specify time to second progression and OS analyses, and address confounding from later treatment access.
• Co-develop the diagnostic. Align drug and test filings across the FDA, the EU, and Japan.

Trial conduct matters too.

Inspectors now apply ICH E6(R3) expectations to complex designs, as Pharmatica’s MHRA GCP inspection guidance Insights explains.

Portfolio leaders should also ask where else a monitoring-triggered switch could apply. Any therapy area with predictable acquired resistance may attract similar designs, so teams should test regulator appetite early through scientific advice meetings.

Commercial teams must plan access too, because testing capacity, payer evidence, and clinician education all shape uptake.

Therefore, Clinical Development teams should ask three questions now. Does our pipeline include resistance biomarkers that appear before imaging progression? Could a diagnostics partner support serial testing at scale? Do our payer dossiers explain why timing, not only the drug, drives value?

Image

Breast Cancer Awareness Month 2026

The camizestrant FDA approval shows how far the FDA will move when a strong progression-free survival outcome meets unmet need, even after a negative advisory vote.

It also shows the price: Accelerated status, a boxed warning, and confirmatory trials still to deliver. Diagnostics, payers, and trial design now form one development plan.

This Breast Cancer Awareness Month, the camizestrant approval offers more than a reason to mark the calendar. It shows that earlier, diagnostics-based decisions may soon shape how people with advanced breast cancer are treated.

The task for the industry is now to prove that benefit, and to make testing accessible to every patient who could use it. 

At Pharmatica, we translate regulatory turning points like this into clear Insights into how data, Regulation, and Market Access connect, so decision-makers can act with confidence when it matters most.

Pharmatica: Insight. Connection. Impact.